Panangyn concentrate for infusions 10 ml. ampoules N5


Additional therapy for chronic heart diseases (heart failure, post-infarction period), heart rhythm disorders, especially ventricular arrhythmias, on the recommendation of a doctor. Additional therapy for treatment with digitalis drugs, on the recommendation of a doctor. As a Supplement to the diet to increase the levels of magnesium and potassium in the body.



Panangyn composition
active substances: magnesium asparagine, potassium asparagine;
1 ml of concentrate for solution for infusion contains 40 mg of magnesium asparagine (corresponding to 3.37 mg of magnesium) and 45.2 mg of potassium asparagine (corresponding to 10.33 mg of potassium);
Excipient: water for injections.

Dosage form
Concentrate for solution for infusion.

Pharmacological properties
Potassium and magnesium ions as important intracellular cations are involved in the work of a number of enzymes, in the process of binding macromolecules to subcellular elements and in the mechanism of muscle contraction at the molecular level. The ratio of extra- and intracellular concentrations of potassium, calcium, sodium and magnesium ions affects the contractility of the myocardium. Asparagine as an endogenous substance is a carrier of potassium and magnesium ions; has a pronounced affinity for cells, its salts are dissociated only to a small extent. As a result, ions penetrate into the intracellular space in the form of complex compounds. Magnesium and potassium asparagine improves the metabolism of the heart muscle. Insufficient intake of potassium and magnesium in the body contributes to the development of hypertension, sclerotic coronary pathology, cardiac arrhythmias, myocardial degeneration.

Panangyn can be recommended for adjunctive therapy in chronic heart disease (heart failure, in the postinfarction period), cardiac arrhythmias, especially in ventricular arrhythmias.
Additional therapy in the treatment of digitalis drugs.


  • Hypersensitivity to the active substances of the drug.
  • Acute and chronic renal failure.
  • Addison’s disease.
  • Atrioventricular block of the III degree.
  • Cardiogenic shock (blood pressure <90 mm Hg).

Experience with the drug in children is insufficient.

Use during pregnancy or breastfeeding
To date, no adverse effects have been reported with the use of the drug in this category of patients.

Method of application and dosage
Panangyn is for intravenous use only. Adults are slowly injected intravenously – 10-20 ml (the contents of one or two ampoules are diluted in 50-100 ml of 5% glucose solution). If necessary, the dose can be re-applied after 4-6 hours. The drug is suitable for combination therapy.
The course of treatment is determined by the doctor.

Cases of overdose are not known.
Due to the ability of the kidneys to excrete large amounts of potassium, increasing the dose of the drug can lead to hyperkalemia only if it is associated with acute or severe impaired potassium excretion.
The therapeutic index of magnesium is wide, and in the absence of renal failure, severe side effects are extremely rare.
Symptoms of hyperkalaemia / hypermagnesemia may occur with rapid intravenous administration.

  • Symptoms of hyperkalemia: general weakness, paresthesia, bradycardia, paralysis. Extremely high plasma potassium levels can be fatal from cardiac depression, arrhythmia, or cardiac arrest.
  • Symptoms of hypermagnesemia: nausea, vomiting, drowsiness, hypotension, bradycardia, weakness, slurred speech, diplopia. At very high plasma concentrations of magnesium, hyporeflexia, muscle paralysis, respiratory arrest, and cardiac arrest may develop.

In case of overdose it is necessary to cancel K + -, Mg2 + -aspartate and to carry out symptomatic treatment (calcium chloride 100 mg / min intravenously, dialysis if necessary).

Side effects
With rapid administration of the drug should take into account the possibility of symptoms of hyperkalemia / hypermagnesemia.

Expiration date
3 years.

Storage conditions
Store at a temperature not exceeding 30 ºC.
Keep out of reach of children.